ArticlePloS one2017
Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01598129 (Exploratory Open Label Study of GM-CSF Coding Oncolytic Adenovirus CGTG-102, With Low Dose Cyclophosphamide in Patients With Refractory Injectable Solid Tumours), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exploratory Open Label Study of GM-CSF Coding Oncolytic Adenovirus CGTG-102, With Low Dose Cyclophosphamide in Patients With Refractory Injectable Solid Tumours
Who cites it
28 citing papers in PubMed.
- Current use of pre-clinical models for evaluation of human adenovirus-based cancer therapeutics.Molecular therapy. Oncology · 2026Review
- Design and Engineering of Recombinant Oncolytic Adenoviruses Expressing an Anti-EpCAM/Anti-CD3 BiTE for Targeted Immunotherapy of A549 Lung Cancer Cells.OncoTargets and therapy · 2026Article
- Biodistribution and toxicity evaluation of oncolytic adenovirus Adf35(OGN) in Syrian hamster and mouse.Cancer gene therapy · 2025Article
- Inducing expression of ICOS-L by oncolytic adenovirus to enhance tumor-specific bi-specific antibody efficacy.Journal of translational medicine · 2024Article
- Next generation oncolytic viruses expressing PADI1 and TIMP2 exhibit anti-tumor activity against melanoma in nude and humanized mouse models.Molecular therapy oncolytics · 2023Article
- Article
- DNA Origami Disguises Herpes Simplex Virus 1 Particles and Controls Their Virulence.Molecules (Basel, Switzerland) · 2022Article
- Recombinant Viral Vectors for Therapeutic Programming of Tumour Microenvironment: Advantages and Limitations.Biomedicines · 2022Review
- Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects.Frontiers in oncology · 2022Review
- From Immunosuppression to Immunomodulation - Turning Cold Tumours into Hot.Journal of Cancer · 2022Article
- Oncolytic Virotherapy in Peritoneal Metastasis Gastric Cancer: The Challenges and Achievements.Frontiers in molecular biosciences · 2022Review
- Article
- Pouring petrol on the flames: Using oncolytic virotherapies to enhance tumour immunogenicity.Immunology · 2021Review
- Polymer Coated Oncolytic Adenovirus to Selectively Target Hepatocellular Carcinoma Cells.Pharmaceutics · 2021Article
- Transgene codon usage drives viral fitness and therapeutic efficacy in oncolytic adenoviruses.NAR cancer · 2021Article
- Oncological Ligand-Target Binding Systems and Developmental Approaches for Cancer Theranostics.Molecular biotechnology · 2021Review
- Article
- Review
- Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein-2 cell entry receptor.Journal of medical virology · 2020Article
- How Computational Chemistry and Drug Delivery Techniques Can Support the Development of New Anticancer Drugs.Molecules (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this work was to carry out preclinical toxicity and bio-distribution studies required for regulatory approval of a clinical trial application for Phase I clinical studies of ONCOS-102 (Ad5/3-D24-GM-CSF) for therapy of advanced cancers (NCT01598129). The study design, route of administration and dosage differs from the clinical protocol and in more detail, investigate bio-distribution and toxicological profile of ONCOS-102 treatment in animal model. The study was carried out in 300 hamsters divided into nine test groups-three bio-distribution groups and six groups for analysis of toxicity. Hamsters received ONCOS-102 by intracardial, intraperitoneal or subcutaneous injections. Additionally, one group was administered twice a week with intraperitoneal injections of Cyclophosphamide. The control animals were administered with NaCl solution without ONCOS-102 in the same volume and the same way. No adverse effects of repeated administration of ONCOS-102 including body weight, food consumption, hematology and clinical chemistry parameters, histopathology and bio-accumulation were observed in the course of 6-month administration and following 3- month recovery period. All obtained findings indicate the treatment clinically safe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.